ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1

Targeted therapy using monoclonal antibodies conjugated to toxins is gaining space in the treatment of cancer. Here, we report the anti-tumor effect of a new antibody drug conjugate (ADC) delivering a HDAC inhibitor to ErbB2+ solid tumors. Trastuzumab was partially reduced with tris [2-carboxyethyl]...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Milazzo, Ferdinando Maria, Vesci, Loredana, Anastasi, Anna Maria, Chiapparino, Caterina, Rosi, Antonio, Giannini, Giuseppe, Taddei, Maurizio, Cini, Elena, Faltoni, Valentina, Petricci, Elena, Battistuzzi, Gianfranco, Salvini, Laura, Carollo, Valeria, De Santis, Rita
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6989603/
https://ncbi.nlm.nih.gov/pubmed/32039017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01534
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky